Transcription factor Nrf2 induces the up-regulation of lncRNA TUG1 to promote progression and adriamycin resistance in urothelial carcinoma of the bladder

References

• Chen C, Lu L, Yan S, et al. Autophagy and doxorubicin resistance in cancer. Anticancer Drugs. 2018;29(1):1–9. doi:10.1097/CAD.000000000000057229099416
   PubMed Web of Science ®Google Scholar
• Smolensky D, Rathore K, Cekanova M. Phosphatidylinositol- 3-kinase inhibitor induces chemosensitivity to a novel derivative of doxorubicin, AD198 chemotherapy in human bladder cancer cells in vitro. BMC Cancer. 2015;15:927. doi:10.1186/s12885-015-1584-326597249
   PubMed Web of Science ®Google Scholar
• Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098–1107. doi:10.1056/NEJMoa111428722992073
   PubMed Web of Science ®Google Scholar
• Tseng CY, Wang JS, Chao MW. Causation by diesel exhaust particles of endothelial dysfunctions in cytotoxicity, pro-inflammation, permeability, and apoptosis induced by ROS generation. Cardiovasc Toxicol. 2016;17(4):384–392.
   Web of Science ®Google Scholar
• Rushworth SA, Macewan DJ. The role of nrf2 and cytoprotection in regulating chemotherapy resistance of human leukemia cells. Cancers. 2011;3(2):1605–1621. doi:10.3390/cancers302160524212776
   PubMedGoogle Scholar
• Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and chemoresistance phenotype. Mol Cancer Ther. 2010;9(8):2365–2376. doi:10.1158/1535-7163.MCT-10-033820682644
   PubMed Web of Science ®Google Scholar
• Bao L, Wu J, Dodson M, et al. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells. Mol Carcinog. 2017;56(6):1543–1553. doi:10.1002/mc.2261528112439
   PubMed Web of Science ®Google Scholar
• S A R, Zaitseva L, M Y M, et al. The high Nrf2 expression in human acute myeloid leukemia is driven by NF-κB and underlies its chemo-resistance. Blood. 2012;120(26):5188–5198. doi:10.1182/blood-2012-04-42212123077289
   PubMed Web of Science ®Google Scholar
• Chen J, Solomides C, Simpkins F, Simpkins H. The role of Nrf2 and ATF2 in resistance to platinum-based chemotherapy. Cancer Chemother Pharmacol. 2017;79(2):369–380. doi:10.1007/s00280-016-3225-128120035
   PubMed Web of Science ®Google Scholar
• Chakravarty D, Sboner A, Nair SS, et al. The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nat Commun. 2014;5:5383. doi:10.1038/ncomms597225415230
   PubMed Web of Science ®Google Scholar
• Huang MD, Chen WM, Qi FZ, et al. Long non-coding RNA ANRIL is upregulated in hepatocellular carcinoma and regulates cell apoptosis by epigenetic silencing of KLF2. J Hematol Oncol. 2015;8:50. doi:10.1186/s13045-015-0153-125966845
   PubMed Web of Science ®Google Scholar
• Li Z, Zhao X, Zhou Y, et al. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. J Transl Med. 2015;13:84. doi:10.1186/s12967-015-0541-x25889214
   PubMed Web of Science ®Google Scholar
• Chen X, Xie R, Gu P, et al. Long noncoding RNA LBCS inhibits self-renewal and chemoresistance of bladder cancer stem cells through epigenetic silencing of SOX2. Clin Cancer Res. 2018;25(4):1389–1403.
   Web of Science ®Google Scholar
• Katsushima K, Natsume A, Ohka F, et al Targeting the Notch-regulated non-coding RNA TUG1 for glioma treatment. Nat Commun. 2016;7:13616. doi:10.1038/ncomms1361627922002
   PubMed Web of Science ®Google Scholar
• Xu C, Guo Y, Liu H, Chen G, Yan Y, Liu T. TUG1 confers cisplatin resistance in esophageal squamous cell carcinoma by epigenetically suppressing PDCD4 expression via EZH2. Cell Biosci. 2018;8:61. doi:10.1186/s13578-018-0260-030519392
   PubMed Web of Science ®Google Scholar
• Han Y, Liu Y, Gui Y, Cai Z. Long intergenic non-coding RNA TUG1 is overexpressed in urothelial carcinoma of the bladder. J Surg Oncol. 2013;107(5):555–559. doi:10.1002/jso.2326422961206
   PubMed Web of Science ®Google Scholar
• Li Q, Song W, Wang J. TUG1 confers Adriamycin resistance in acute myeloid leukemia by epigenetically suppressing miR-34a expression via EZH2. Biomed Pharmacother. 2019;109:1793–1801. doi:10.1016/j.biopha.2018.11.00330551433
   PubMed Web of Science ®Google Scholar
• Xie D, Zhang H, Hu X, Shang C. Knockdown of long non-coding RNA Taurine Up-Regulated 1 inhibited doxorubicin resistance of bladder urothelial carcinoma via Wnt/β-catenin pathway. Oncotarget. 2017;8(51):88689–88696. doi:10.18632/oncotarget.v8i5129179467
   PubMedGoogle Scholar
• Gao M, Zhao B, Chen M, et al. Nrf-2-driven long noncoding RNA ODRUL contributes to modulating silver nanoparticle-induced effects on erythroid cells. Biomaterials. 2017;130:14–27. doi:10.1016/j.biomaterials.2017.03.02728351005
   PubMed Web of Science ®Google Scholar
• Zhang Y, Xia J, Li Q, et al. NRF2/Long noncoding RNA ROR signaling regulates mammary stem cell expansion and protects against estrogen genotoxicity. J Biol Chem. 2014;289(45):31310–31318. doi:10.1074/jbc.M114.60486825231996
   PubMed Web of Science ®Google Scholar
• Sun Y, Guan Z, Liang L, et al. HIF-1alpha/MDR1 pathway confers chemoresistance to cisplatin in bladder cancer. Oncol Rep. 2016;35(3):1549–1556. doi:10.3892/or.2015.453626717965
   PubMed Web of Science ®Google Scholar
• Catanzaro E, Calcabrini C, Turrini E, Sestili P, Fimognari C. Nrf2: a potential therapeutic target for naturally occurring anticancer drugs? Expert Opin Ther Targets. 2017;21(8):781–793. doi:10.1080/14728222.2017.135154928675319
   PubMed Web of Science ®Google Scholar
• Rushworth SA, Bowles KM, MacEwan DJ. High basal nuclear levels of Nrf2 in acute myeloid leukemia reduces sensitivity to proteasome inhibitors. Cancer Res. 2011;71(5):1999–2009. doi:10.1158/0008-5472.CAN-10-301821212410
   PubMed Web of Science ®Google Scholar
• Hayden A, Douglas J, Sommerlad M, et al. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer. Urol Oncol. 2014;32(6):806–814. doi:10.1016/j.urolonc.2014.02.00624837013
   PubMed Web of Science ®Google Scholar
• Ciamporcero E, Daga M, Pizzimenti S, et al. Crosstalk between Nrf2 and YAP contributes to maintaining the antioxidant potential and chemoresistance in bladder cancer. Free Radic Biol Med. 2018;115:447–457. doi:10.1016/j.freeradbiomed.2017.12.00529248722
   PubMed Web of Science ®Google Scholar
• Bialk P, Wang Y, Banas K, Kmiec EB. Functional gene knockout of NRF2 increases chemosensitivity of human lung cancer A549 cells in vitro and in a xenograft mouse model. Mol Ther Oncolytics. 2018;11:75–89. doi:10.1016/j.omto.2018.10.00230505938
   PubMed Web of Science ®Google Scholar
• Tang T, Cheng Y, She Q, et al. Long non-coding RNA TUG1 sponges miR-197 to enhance cisplatin sensitivity in triple negative breast cancer. Biomed Pharmacother. 2018;107:338–346. doi:10.1016/j.biopha.2018.07.07630098551
   PubMed Web of Science ®Google Scholar
• Han X, Yang Y, Sun Y, Qin L, Yang Y. LncRNA TUG1 affects cell viability by regulating glycolysis in osteosarcoma cells. Gene. 2018;674:87–92. doi:10.1016/j.gene.2018.06.08529960067
   PubMed Web of Science ®Google Scholar
• Niu Y, Ma F, Huang W, et al. Long non-coding RNA TUG1 is involved in cell growth and chemoresistance of small cell lung cancer by regulating LIMK2b via EZH2. Mol Cancer. 2017;16(1):5. doi:10.1186/s12943-016-0575-628069000
   PubMedGoogle Scholar
• Yang F, Li X, Zhang L, Cheng L, Li X. LncRNA TUG1 promoted viability and associated with gemcitabine resistant in pancreatic ductal adenocarcinoma. J Pharmacol Sci. 2018;137(2):116–121. doi:10.1016/j.jphs.2018.06.00229960845
   PubMed Web of Science ®Google Scholar
• Fraczek N, Bronisz I, Pietryka M, et al. An outline of main factors of drug resistance influencing cancer therapy. J Chemother. 2016;28(6):457–464. doi:10.1080/1120009X.2016.121815827545330
   PubMed Web of Science ®Google Scholar
• Gottesman MM, Lavi O, Hall MD, Gillet JP. Toward a better understanding of the complexity of cancer drug resistance. Annu Rev Pharmacol Toxicol. 2016;56:85–102. doi:10.1146/annurev-pharmtox-010715-10311126514196
   PubMed Web of Science ®Google Scholar
• Shaffer BC, Gillet JP, Patel C, Baer MR, Bates SE, Gottesman MM. Drug resistance: still a daunting challenge to the successful treatment of AML. Drug Resist Updat. 2012;15(1–2):62–69. doi:10.1016/j.drup.2012.02.00122409994
   PubMed Web of Science ®Google Scholar
• Silva R, Vilas-Boas V, Carmo H, et al. Modulation of P-glycoprotein efflux pump: induction and activation as a therapeutic strategy. Pharmacol Ther. 2015;149:1–123. doi:10.1016/j.pharmthera.2014.11.01325435018
   PubMed Web of Science ®Google Scholar
• Vallo S, Kopp R, Michaelis M, et al. Resistance to nanoparticle albumin-bound paclitaxel is mediated by ABCB1 in urothelial cancer cells. Oncol Lett. 2017;13(6):4085–4092. doi:10.3892/ol.2017.598628599410
   PubMed Web of Science ®Google Scholar
• M R S, Jeddi F, Soozangar N, et al. Nrf2/P–glycoprotein axis is associated with clinicopathological characteristics in colorectal cancer. Biomed Pharmacother. 2018;104:458–464. doi:10.1016/j.biopha.2018.05.06229793178
   PubMed Web of Science ®Google Scholar
• Ye P, Mimura J, Okada T, et al. Nrf2- and ATF4-dependent upregulation of xCT modulates the sensitivity of T24 bladder carcinoma cells to proteasome inhibition. Mol Cell Biol. 2014;34(18):3421–3434. doi:10.1128/MCB.00221-1425002527
   PubMed Web of Science ®Google Scholar
• Jiang H, Hu X, Zhang H, Li WB. Down-regulation of LncRNA TUG1 enhances radiosensitivity in bladder cancer via suppressing HMGB1 expression. Radiat Oncol. 2017;12(1):65. doi:10.1186/s13014-017-0802-328376901
   PubMed Web of Science ®Google Scholar